B
Bull
Bull · 25%PYPD
$4.99
情境價格
$5.070
-0.050 (-0.98%)收盤時
Loading chart…
- High
- 5.145
- Open
- 5.130
- VWAP
- 5.07
- Vol
- 63.72K
- Mkt Cap
- 20.15M
- Low
- 4.985
- Amount
- 322.86K
- EV/EBITDA, TTM
- 0.00
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
AI analysis of PolyPid Ltd (PYPD)
buyPolyPid Ltd appears to be a good buy right now due to its current price of $5.07, which is significantly below the analyst price target of $12, indicating a potential upside of 136%. Additionally, the stock has shown a strong 1-year change of +48.68%, suggesting positive momentum. However, the main risk is the company's ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which could impact future performance.
估值指標
The current forward P/E ratio for PolyPid Ltd (PYPD) is 0.00, compared to its 5-year average forward P/E of -1.56.
Alphio AI Price Scenarios for PYPD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
9.508-19NASDAQ.COMPolyPid Reports Q2 Loss Reduction Amid Strategic Partnerships
9.007-29seekingalphaPolyPid Receives FDA Priority Review for D-PLEX100
9.007-29NASDAQ.COMPolyPid's D-PLEX100 Receives FDA Priority Review
9.007-29GlobenewswirePolyPid's D-PLEX100 Receives FDA Priority Review
9.007-29NewsfilterPolyPid's D-PLEX100 Receives FDA Priority Review
PYPD FAQ — answered by Alphio AI
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
PolyPid Ltd appears to be a good buy right now due to its current price of $5.07, which is significantly below the analyst price target of $12, indicating a potential upside of 136%. Additionally, the stock has shown a strong 1-year change of +48.68%, suggesting positive momentum. However, the main risk is the company's ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which could impact future performance.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。